MicroRNAs: short non-coding players in cancer chemoresistance

  • Sara Donzelli
  • Federica Mori
  • Francesca Biagioni
  • Teresa Bellissimo
  • Claudio Pulito
  • Paola Muti
  • Sabrina Strano
  • Giovanni Blandino
Keywords: Chemoresistance, MicroRNA, Multiple drug resistance

Abstract

Chemoresistance is one of the main problems in the therapy of cancer. There are a number of different molecular mechanisms through which a cancer cell acquires resistance to a specific treatment, such as alterations in drug uptake, drug metabolism and drug targets. There are several lines of evidence showing that miRNAs are involved in drug sensitivity of cancer cells in different tumor types and by different treatments. In this review, we provide an overview of the more recent and significant findings on the role of miRNAs in cancer cell drug resistance. In particular, we focus on specific miRNA mechanisms of action that in various steps lead from drug cell sensitivity to drug cell resistance. We also provide evidence on how miRNA profiling may unveil relevant predictive biomarkers for therapy outcomes.

Downloads

Download data is not yet available.

References

Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 2002, 53: 615-627. 10.1146/annurev.med.53.082901.103929.

CrossRefPubMedGoogle Scholar

Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, Sharon E, Spector Y, Bentwich Z: Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 2005, 37: 766-770. 10.1038/ng1590.

CrossRefPubMedGoogle Scholar

Cai X, Hagedorn CH, Cullen BR: Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA. 2004, 10: 1957-1966. 10.1261/rna.7135204.

PubMedCentralCrossRefPubMedGoogle Scholar

Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN: MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004, 23: 4051-4060. 10.1038/sj.emboj.7600385.

PubMedCentralCrossRefPubMedGoogle Scholar

Han J, Lee Y, Yeom KH, Nam JW, Heo I, Rhee JK, Sohn SY, Cho Y, Zhang BT, Kim VN: Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell. 2006, 125: 887-901. 10.1016/j.cell.2006.03.043.

CrossRefPubMedGoogle Scholar

Yi R, Qin Y, Macara IG, Cullen BR: Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003, 17: 3011-3016. 10.1101/gad.1158803.

PubMedCentralCrossRefPubMedGoogle Scholar

Bohnsack MT, Czaplinski K, Gorlich D: Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA. 2004, 10: 185-191. 10.1261/rna.5167604.

PubMedCentralCrossRefPubMedGoogle Scholar

Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K, Shiekhattar R: TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature. 2005, 436: 740-744. 10.1038/nature03868.

PubMedCentralCrossRefPubMedGoogle Scholar

Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R: Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell. 2005, 123: 631-640. 10.1016/j.cell.2005.10.022.

CrossRefPubMedGoogle Scholar

Pasquinelli AE: MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012, 13: 271-282.

PubMedGoogle Scholar

Iorio MV, Croce CM: MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012, 4: 143-159. 10.1002/emmm.201100209.

PubMedCentralCrossRefPubMedGoogle Scholar

Lim PK, Bliss SA, Patel SA, Taborga M, Dave MA, Gregory LA, Greco SJ, Bryan M, Patel PS, Rameshwar P: Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 2011, 71: 1550-1560. 10.1158/0008-5472.CAN-10-2372.

CrossRefPubMedGoogle Scholar

Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML, Karlsson JM, Baty CJ, Gibson GA, Erdos G, Wang Z, Milosevic J, Tkacheva OA, Divito SJ, Jordan R, Lyons-Weiler J, Watkins SC, Morelli AE: Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood. 2012, 119: 756-766. 10.1182/blood-2011-02-338004.

PubMedCentralCrossRefPubMedGoogle Scholar

Zheng T, Wang J, Chen X, Liu L: Role of microRNA in anticancer drug resistance. Int J Cancer. 2010, 126: 2-10. 10.1002/ijc.24782.

CrossRefPubMedGoogle Scholar

Wilson TR, Longley DB, Johnston PG: Chemoresistance in solid tumours. Ann Oncol. 2006, 17 (Suppl 10): x315-324. 10.1093/annonc/mdl280.

CrossRefPubMedGoogle Scholar

Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, Adair B, Vannini I, Fanini F, Bottoni A, Costinean S, Sandhu SK, Nuovo GJ, Alder H, Gafa R, Calore F, Ferracin M, Lanza G, Volinia S, Negrini M, McIlhatton MA, Amadori D, Fishel R, Croce CM: Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A. 2010, 107: 6982-6987. 10.1073/pnas.1002472107.

PubMedCentralCrossRefPubMedGoogle Scholar

Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, Nuovo GJ, Fishel R, Croce CM: MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A. 2010, 107: 21098-21103. 10.1073/pnas.1015541107.

PubMedCentralCrossRefPubMedGoogle Scholar

Wang Y, Huang JW, Li M, Cavenee WK, Mitchell PS, Zhou X, Tewari M, Furnari FB, Taniguchi T: MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol Cancer Res. 2011, 9: 1100-1111. 10.1158/1541-7786.MCR-11-0007.

PubMedCentralCrossRefPubMedGoogle Scholar

Wu CW, Dong YJ, Liang QY, He XQ, Ng SS, Chan FK, Sung JJ, Yu J: MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer. PLoS One. 2013, 8: e57036-10.1371/journal.pone.0057036.

PubMedCentralCrossRefPubMedGoogle Scholar

Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L, Piazza S, Cappelletti V, Daidone M, Agami R, Del Sal G: Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle. 2013, 12: 1679-87. 10.4161/cc.24757.

PubMedCentralCrossRefPubMedGoogle Scholar

Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, Weinstock DM, Gorospe M, Harris AL, Helleday T, Chowdhury D: miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011, 41: 210-220. 10.1016/j.molcel.2010.12.005.

PubMedCentralCrossRefPubMedGoogle Scholar

Wilson TR, Johnston PG, Longley DB: Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets. 2009, 9: 307-319. 10.2174/156800909788166547.

CrossRefPubMedGoogle Scholar

Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science. 1994, 266: 807-810. 10.1126/science.7973635.

CrossRefPubMedGoogle Scholar

Iida K, Fukushi J, Matsumoto Y, Oda Y, Takahashi Y, Fujiwara T, Fujiwara-Okada Y, Hatano M, Nabashima A, Kamura S, Iwamoto Y: miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int. 2013, 13: 21-10.1186/1475-2867-13-21.

PubMedCentralCrossRefPubMedGoogle Scholar

Hermeking H: p53 enters the microRNA world. Cancer Cell. 2007, 12: 414-418. 10.1016/j.ccr.2007.10.028.

CrossRefPubMedGoogle Scholar

Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, Deguchi T, Ito M: Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 2008, 377: 114-119. 10.1016/j.bbrc.2008.09.086.

CrossRefPubMedGoogle Scholar

Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M, Bolondi L: MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2009, 69: 5761-5767. 10.1158/0008-5472.CAN-08-4797.

CrossRefPubMedGoogle Scholar

Ohtsuka T, Ryu H, Minamishima YA, Ryo A, Lee SW: Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation. Oncogene. 2003, 22: 1678-1687. 10.1038/sj.onc.1206306.

CrossRefPubMedGoogle Scholar

Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science. 1991, 253: 49-53. 10.1126/science.1905840.

CrossRefPubMedGoogle Scholar

Hainaut P, Hollstein M: p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000, 77: 81-137.

CrossRefPubMedGoogle Scholar

Ory K, Legros Y, Auguin C, Soussi T: Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 1994, 13: 3496-3504.

PubMedCentralPubMedGoogle Scholar

Blandino G, Levine AJ, Oren M: Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 1999, 18: 477-485. 10.1038/sj.onc.1202314.

CrossRefPubMedGoogle Scholar

Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A: Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene. 2006, 25: 304-309.

PubMedGoogle Scholar

Cadwell C, Zambetti GP: The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene. 2001, 277: 15-30. 10.1016/S0378-1119(01)00696-5.

CrossRefPubMedGoogle Scholar

Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, Del Bufalo D, Strano S, Blandino G: The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol. 2009, 16: 1086-1093. 10.1038/nsmb.1669.

CrossRefPubMedGoogle Scholar

Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G, Piaggio G: Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell. 2006, 10: 191-202. 10.1016/j.ccr.2006.08.013.

CrossRefPubMedGoogle Scholar

Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, Levine AJ, Sacchi A, Cesareni G, Oren M, Blandino G: Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem. 2000, 275: 29503-29512. 10.1074/jbc.M003360200.

CrossRefPubMedGoogle Scholar

Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M, Blandino G: Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem. 2002, 277: 18817-18826. 10.1074/jbc.M201405200.

CrossRefPubMedGoogle Scholar

Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, Blandino G: Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene. 2013, 33: 1601-8.

CrossRefPubMedGoogle Scholar

Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, Blandino G: MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ. 2012, 19: 1038-1048. 10.1038/cdd.2011.190.

PubMedCentralCrossRefPubMedGoogle Scholar

Ganci F, Sacconi A, Bossel Ben-Moshe N, Manciocco V, Sperduti I, Strigari L, Covello R, Benevolo M, Pescarmona E, Domany E, Muti P, Strano S, Spriano G, Fontemaggi G, Blandino G: Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann Oncol. 2013, 24: 3082-3088. 10.1093/annonc/mdt380.

PubMedCentralCrossRefPubMedGoogle Scholar

Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006, 130: 2113-2129. 10.1053/j.gastro.2006.02.057.

CrossRefPubMedGoogle Scholar

Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007, 133: 647-658. 10.1053/j.gastro.2007.05.022.

PubMedCentralCrossRefPubMedGoogle Scholar

Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, Danesi R, Campani D, Verheul HM, Boggi U: MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010, 70: 4528-4538. 10.1158/0008-5472.CAN-09-4467.

CrossRefPubMedGoogle Scholar

Yang SM, Huang C, Li XF, Yu MZ, He Y: Li J: miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology. 2013, 306: 162-168.

CrossRefPubMedGoogle Scholar

Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, Ji Z, Zhao J, Zhao H, Guo M, Ma Q, Xiao C, Fan Q, Ma B: MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One. 2013, 8: e53906-10.1371/journal.pone.0053906.

PubMedCentralCrossRefPubMedGoogle Scholar

Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68: 425-433. 10.1158/0008-5472.CAN-07-2488.

CrossRefPubMedGoogle Scholar

Wang YS, Wang YH, Xia HP, Zhou SW, Schmid-Bindert G, Zhou CC: MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac J Cancer Prev. 2012, 13: 255-260. 10.7314/APJCP.2012.13.1.255.

CrossRefPubMedGoogle Scholar

Liang Z, Li Y, Huang K, Wagar N, Shim H: Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res. 2011, 28: 3091-3100. 10.1007/s11095-011-0570-y.

PubMedCentralCrossRefPubMedGoogle Scholar

Li J, Zhang Y, Zhao J, Kong F, Chen Y: Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem. 2011, 357: 31-38. 10.1007/s11010-011-0872-8.

CrossRefPubMedGoogle Scholar

Rao E, Jiang C, Ji M, Huang X, Iqbal J, Lenz G, Wright G, Staudt LM, Zhao Y, McKeithan TW, Chan WC, Fu K: The miRNA-17 approximately 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia. 2012, 26: 1064-1072. 10.1038/leu.2011.305.

CrossRefPubMedGoogle Scholar

Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C, Bolon B, Condorelli G, Croce CM: MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc Natl Acad Sci U S A. 2012, 109: 16570-16575. 10.1073/pnas.1207917109.

PubMedCentralCrossRefPubMedGoogle Scholar

Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K, Yamamoto H, Ishii H, Doki Y, Mori M: MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol. 2012, 19: 3065-3071. 10.1245/s10434-012-2246-1.

CrossRefPubMedGoogle Scholar

Wang F, Liu M, Li X, Tang H: MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett. 2013, 587: 488-495. 10.1016/j.febslet.2013.01.016.

CrossRefPubMedGoogle Scholar

Qu J, Zhao L, Zhang P, Wang J, Xu N, Mi W, Jiang X, Zhang C: MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA. J Cell Physiol. 2013, doi:10.1002/jcp.24366

Google Scholar

Ryan J, Tivnan A, Fay J, Bryan K, Meehan M, Creevey L, Lynch J, Bray IM, O'Meara A, Davidoff AM, Stallings RL: MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer. 2012, 107: 967-976. 10.1038/bjc.2012.356.

PubMedCentralCrossRefPubMedGoogle Scholar

Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A, Blandino G: miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis. 2012, 3: e423-10.1038/cddis.2012.160.

PubMedCentralCrossRefPubMedGoogle Scholar

Tsang WP, Kwok TT: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis. 2008, 13: 1215-1222. 10.1007/s10495-008-0256-z.

CrossRefPubMedGoogle Scholar

Quintavalle C, Donnarumma E, Iaboni M, Roscigno G, Garofalo M, Romano G, Fiore D, De Marinis P, Croce CM, Condorelli G: Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene. 2012, 32: 4001-8.

CrossRefPubMedGoogle Scholar

Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008, 283: 29897-29903. 10.1074/jbc.M804612200.

PubMedCentralCrossRefPubMedGoogle Scholar

Fotoohi AK, Albertioni F: Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk Lymphoma. 2008, 49: 410-426. 10.1080/10428190701824569.

CrossRefPubMedGoogle Scholar

Gottesman MM, Ling V: The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 2006, 580: 998-1009. 10.1016/j.febslet.2005.12.060.

CrossRefPubMedGoogle Scholar

Dean M, Rzhetsky A, Allikmets R: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001, 11: 1156-1166. 10.1101/gr.GR-1649R.

CrossRefPubMedGoogle Scholar

Litman T, Druley TE, Stein WD, Bates SE: From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci. 2001, 58: 931-959. 10.1007/PL00000912.

CrossRefPubMedGoogle Scholar

Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S: Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol. 2012, 180: 2490-2503. 10.1016/j.ajpath.2012.02.024.

PubMedCentralCrossRefPubMedGoogle Scholar

Wang F, Li T, Zhang B, Li H, Wu Q, Yang L, Nie Y, Wu K, Shi Y, Fan D: MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun. 2013, 434: 688-694. 10.1016/j.bbrc.2013.04.010.

CrossRefPubMedGoogle Scholar

Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM: Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008, 76: 582-588. 10.1016/j.bcp.2008.06.007.

PubMedCentralCrossRefPubMedGoogle Scholar

Liao R, Sun J, Zhang L, Lou G, Chen M, Zhou D, Chen Z, Zhang S: MicroRNAs play a role in the development of human hematopoietic stem cells. J Cell Biochem. 2008, 104: 805-817. 10.1002/jcb.21668.

CrossRefPubMedGoogle Scholar

To KK, Zhan Z, Litman T, Bates SE: Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol. 2008, 28: 5147-5161. 10.1128/MCB.00331-08.

PubMedCentralCrossRefPubMedGoogle Scholar

Pan YZ, Morris ME, Yu AM: MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol. 2009, 75: 1374-1379. 10.1124/mol.108.054163.

PubMedCentralCrossRefPubMedGoogle Scholar

Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T: MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 2006, 66: 9090-9098. 10.1158/0008-5472.CAN-06-1403.

CrossRefPubMedGoogle Scholar

Takagi S, Nakajima M, Mohri T, Yokoi T: Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem. 2008, 283: 9674-9680. 10.1074/jbc.M709382200.

CrossRefPubMedGoogle Scholar

Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 2008, 7: 2152-2159. 10.1158/1535-7163.MCT-08-0021.

CrossRefPubMedGoogle Scholar

Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM: MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009, 113: 249-255. 10.1016/j.ygyno.2009.01.014.

CrossRefPubMedGoogle Scholar

Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008, 111: 478-486. 10.1016/j.ygyno.2008.08.017.

CrossRefPubMedGoogle Scholar

Park YT, Jeong JY, Lee MJ, Kim KI, Kim TH, Kwon YD, Lee C, Kim OJ, An HJ: MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance. J Ovarian Res. 2013, 6: 18-10.1186/1757-2215-6-18.

PubMedCentralCrossRefPubMedGoogle Scholar

Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, Liu CG, Croce CM, Condorelli G: MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene. 2008, 27: 3845-3855. 10.1038/onc.2008.6.

CrossRefPubMedGoogle Scholar

Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, Guo B: Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010, 1: e105-10.1038/cddis.2010.85.

PubMedCentralCrossRefPubMedGoogle Scholar

Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, Choi IJ, Munroe DJ, Green JE: miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics. 2011, 4: 79-10.1186/1755-8794-4-79.

PubMedCentralCrossRefPubMedGoogle Scholar

Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G, Calin GA, Liu CG, Bloomfield CD, Andreeff M, Croce CM: MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A. 2006, 103: 5078-5083. 10.1073/pnas.0600587103.

PubMedCentralCrossRefPubMedGoogle Scholar

Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6: 259-269. 10.1038/nrc1840.

CrossRefPubMedGoogle Scholar

Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso G, Strano S, Muti P, Mottolese M, Yarden Y, Domany E, Blandino G: miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med. 2012, 4: 1214-1229. 10.1002/emmm.201201483.

PubMedCentralCrossRefPubMedGoogle Scholar

Cioce M, Ganci F, Canu V, Sacconi A, Mori F, Canino C, Korita E, Casini B, Alessandrini G, Cambria A, Carosi MA, Blandino R, Panebianco V, Facciolo F, Visca P, Volinia S, Muti P, Strano S, Croce CM, Pass HI, Blandino G: Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene. 2013, doi:10.1038/onc.2013.476.

Google Scholar

Bader AG, Brown D, Winkler M: The promise of microRNA replacement therapy. Cancer Res. 2010, 70: 7027-7030. 10.1158/0008-5472.CAN-10-2010.

PubMedCentralCrossRefPubMedGoogle Scholar

Kumar A, Jeang KT: Insights into cellular microRNAs and human immunodeficiency virus type 1 (HIV-1). J Cell Physiol. 2008, 216: 327-331. 10.1002/jcp.21488.

CrossRefPubMedGoogle Scholar

Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C, Bartucci M, Muto G, Peschle C, De Maria R: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008, 14: 1271-1277. 10.1038/nm.1880.

CrossRefPubMedGoogle Scholar

Boudreau RL, Monteys AM, Davidson BL: Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA. 2008, 14: 1834-1844. 10.1261/rna.1062908.

PubMedCentralCrossRefPubMedGoogle Scholar

Bauer M, Kinkl N, Meixner A, Kremmer E, Riemenschneider M, Forstl H, Gasser T, Ueffing M: Prevention of interferon-stimulated gene expression using microRNA-designed hairpins. Gene Ther. 2009, 16: 142-147. 10.1038/gt.2008.123.

CrossRefPubMedGoogle Scholar

Broderick JA, Zamore PD: MicroRNA therapeutics. Gene Ther. 2011, 18: 1104-1110. 10.1038/gt.2011.50.

PubMedCentralCrossRefPubMedGoogle Scholar

Lu DP, Read RL, Humphreys DT, Battah FM, Martin DI, Rasko JE: PCR-based expression analysis and identification of microRNAs. J RNAi Gene Silencing. 2005, 1: 44-49.

PubMedCentralPubMedGoogle Scholar

Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T: Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007, 39: 673-677. 10.1038/ng2003.

CrossRefPubMedGoogle Scholar

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW: MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009, 361: 1437-1447. 10.1056/NEJMoa0901282.

PubMedCentralCrossRefPubMedGoogle Scholar

Yu SL, Chen HY, Yang PC, Chen JJ: Unique MicroRNA signature and clinical outcome of cancers. DNA Cell Biol. 2007, 26: 283-292. 10.1089/dna.2006.0555.

CrossRefPubMedGoogle Scholar

Miravirsen works against hepatitis C virus. BMJ. 2013, 346: f2069.

Google Scholar

Published
2019-01-31
Section
Review